Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Torrent To Build ‘Future Brazil’ In Mexico, Open To Acquisitions In India

Januvia Generic Sees Strong Competition

Executive Summary

Torrent is upping its ambitions in Mexico, the second-largest market in Latin America, where it is to set up a manufacturing hub along with other Indian companies. As sales in the US stagnate, it's also on the acquisition path in India. Meanwhile, building market share for its Januvia generic is going to be an uphill task.

You may also be interested in...



Januvia Generics Arrive: Can MSD Defend Its Turf In India?

A wave of cut-price sitagliptin generics is seen hitting the Indian market with expiry of the patent on Merck’s Januvia, a product that has had a hugely eventful journey over the years including fending off pre-expiry challengers. Will the company respond with price cuts?

Torrent Acquires Chronic Brands From Dr. Reddy’s, Folds Up US Liquids Business

Torrent is recalibrating strategy with the addition of chronic therapies from Dr. Reddy’s while it folds up an unsustainable liquids business in US. The latter resulted in the company reporting a Q4 loss but a timely bonus share issue propped up investor sentiment.

Aczone Generic Approval In Sight, All Clear At Sites Key To Torrent’s US Outlook

Torrent expects US FDA’s final approval for Allergan/Almirall’s Aczone, a dapsone formulation for acne vulgaris, in February, even as it awaits regulatory clearance for manufacturing sites. Meanwhile, it has launched molnupiravir in India and is hiking its domestic sales force by 400-500.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146819

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel